ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1564

Feasibility of Ultra-low-dose, Short-duration, Total-body Evaluation of Inflammatory Arthritis Using uEXPLORER 18F-FDG PET/CT

Soumajyoti Sarkar1, Siba Raychaudhuri2, Lorenzo Nardo3, Heather Hunt3, Denise Caudle4, Mike Nguyen4, Simon Cherry4, Ramsey Badawi4, Abhijit Chaudhari5 and Yasser Abdelhafez3, 1University of California, Davis, Davis, 2Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, 3University of California Davis, Sacramento, CA, 4University of California Davis, Sacramento, 5University of California, Davis, Sacramento, CA

Meeting: ACR Convergence 2020

Keywords: Imaging, Osteoarthritis, Psoriatic arthritis, rheumatoid arthritis, Systems-based Studies

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: The uEXPLORER system enables the unique, simultaneous acquisition of PET data over the entire adult human body with a high-sensitivity, alongside concurrent CT data. We hypothesized that these unique characteristics of the uEXPLORER system will yield shorter scan time and reduction in radiation dose, both crucial to an arthritic population. We aimed to prospectively (1) document the glucose uptake patterns – using the radiotracer 18F-FDG – in arthritic lesions across the entire body of participants with established rheumatoid arthritis (RA), psoriatic arthritis (PsA) and osteoarthritis (OA); and (2) evaluate the influence of shortening the scan time or dose reduction on image quality.

Methods: An ultra-low-dose 18F-FDG scanning protocol was employed in 14 patients (all males, 59±13 yrs) with RA (n=3), PsA (n=8) or OA (n=3) (injected radiotracer dose 75.5±4.4 MBq (1/5th of standard clinical dose)). PET/CT scans were acquired for 20-min starting at 40-min after the injection of 18F-FDG; data were then reconstructed as a single frame (20-min long), four 5-min frames, and twenty 1-min frames, using the same standard protocol. A single volume of interest (VOI) >3cm3 was drawn on the ascending aorta as a background blood pool [BP], and on arthritic lesions to calculate target-to-background ratio (TBR). Coefficient of variation (COV%) was used to estimate image noise and was calculated from the VOIs in the BP.

Results: uEXPLORER scans were successfully conducted for the 14 participants. The entire body was in the field-of-view in all participants. The effective dose from the PET radiotracer and ultra-low-dose CT was approximately 2.7 mSv compared to typically ~14-15 mSv for clinical PET/CT scans on standard scanners. When evaluating the most active lesion, the average TBR was 1.3±0.4. The COV for the 20-min, 5-min, and 1-min scans were (median [range]): 8 [6,13], 15 [8,25], 31 [16, 57]. Qualitatively, all lesions detected on 20-min images could also be seen on 5-min images. Although lesions were still visualized on 1-min frames (TBR=1.4±0.5), the surrounding tissue background was elevated, and the image quality was sub-optimal.

Conclusion: All joints of the body could be visualized simultaneously and assessed in the same phase of radiotracer uptake on uEXPLORER PET/CT scans. Scan times as short as 5-min, with 1/5th of the standard 18F-FDG dose, appeared to be feasible and provide image quality not inferior to the full 20-min PET/CT scan. Further work is warranted to evaluate the methods on more participants, and further develop software-based methods to enhance the image quality of shorter duration scans.

Maximum intensity projection total body images of a 72-year-old male (172 cm, 85 kg) with established diagnosis of psoriatic arthritis. Images were acquired for 20-min duration starting at 40-min after IV injection of 77.6 MBq of 18F-FDG. Images were further subsampled in software into 5-min and 1-min frames. Note that changes in tracer intensity in the left shoulder (arrow) and wrist (arrowhead) are preserved over the different frames.


Disclosure: S. Sarkar, None; S. Raychaudhuri, AbbVie, 2, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sun Pharmaceutical Industries, Inc., 2, Amgen, 5, Eli Lilly, 5; L. Nardo, United Imaging, 9; H. Hunt, None; D. Caudle, None; M. Nguyen, None; S. Cherry, United Healthcare, 2; R. Badawi, United Imaging Healthcare, 2; A. Chaudhari, None; Y. Abdelhafez, None.

To cite this abstract in AMA style:

Sarkar S, Raychaudhuri S, Nardo L, Hunt H, Caudle D, Nguyen M, Cherry S, Badawi R, Chaudhari A, Abdelhafez Y. Feasibility of Ultra-low-dose, Short-duration, Total-body Evaluation of Inflammatory Arthritis Using uEXPLORER 18F-FDG PET/CT [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/feasibility-of-ultra-low-dose-short-duration-total-body-evaluation-of-inflammatory-arthritis-using-uexplorer-18f-fdg-pet-ct/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/feasibility-of-ultra-low-dose-short-duration-total-body-evaluation-of-inflammatory-arthritis-using-uexplorer-18f-fdg-pet-ct/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology